Drug intelligence / Profile preview

etoricoxib + flavoxate

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of etoricoxib and flavoxate. Etoricoxib is a selective COX-2 inhibitor used to treat various forms of arthritis, acute pain, and gout. Flavoxate is an anticholinergic medication used to treat bladder spasms and relieve difficult urination. The combination has been studied for reducing morphine requirements after transurethral prostatectomy (TURP).

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on etoricoxib + flavoxate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etoricoxib + flavoxate.

Explore the full profile